Compare TPC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | RLAY |
|---|---|---|
| Founded | 1894 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2003 | 2020 |
| Metric | TPC | RLAY |
|---|---|---|
| Price | $81.20 | $17.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $86.00 | $19.50 |
| AVG Volume (30 Days) | 687.5K | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 148.24 | 31.78 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $5,543,039,000.00 | $15,355,000.00 |
| Revenue This Year | $15.37 | N/A |
| Revenue Next Year | $9.99 | $324.03 |
| P/E Ratio | $178.69 | ★ N/A |
| Revenue Growth | 28.11 | ★ 53.44 |
| 52 Week Low | $43.52 | $3.03 |
| 52 Week High | $100.00 | $20.79 |
| Indicator | TPC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 47.80 |
| Support Level | $80.00 | $6.67 |
| Resistance Level | $88.28 | $20.59 |
| Average True Range (ATR) | 2.90 | 1.10 |
| MACD | 0.52 | -0.33 |
| Stochastic Oscillator | 50.20 | 8.55 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.